Search Results
Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
cytopenia-sparing safety across 12 cohorts up to 36 mg/kg QWNo bleeding events or immune-related toxicities, with the majority of treatment-related adverse events being Grade 1-2Linear PK (T1/2 ~3 days) with receptor occupancy (RO) >99% at ≥8 mg/kgDurable antitumor activity,
More news about: HanchorBio Inc.
Dec 11, 2025, 07:07 ET Odyssey Functional Energy Expands Across Major U.S. Airports Nationwide with CIBO Express Deal
ingredients and no added sugar. With bold, craveable flavors, Odyssey provides clean, functional energy without the crash, available in both 222mg and 85mg caffeine formats to power whatever the day demands. Odyssey products are Non-GMO, Vegan, Gluten-Free, Kosher, and made with real fruit juice.Odyssey
More news about: Odyssey Functional Energy
Dec 11, 2025, 07:00 ET Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
stomatitis (Grade 3) at the 2.75 mg/kg Q3W dose. As of the clinical cutoff date, a total of 31 participants were treated with the combination of BHV-1510 and cemiplimab, with BHV-1510 doses ranging from 2-2.75 mg/kg Q3W and 1.25-1.5 mg/kg D1D8Q3W. Cemiplimab was given at 350 mg Q3W.Across all doses
More news about: Biohaven Ltd.
Dec 11, 2025, 06:45 ET Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg).The initial TRIUMPH Phase 3 global registrational
More news about: Eli Lilly and Company
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
Elacestranto 345 mg uma vez ao dia + Everolimo 7,5mg uma vez ao dia (n=50)
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
Elacestrant 345 mg una vez al día + Everolimus 7,5 mg una vez al día (n=50)
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 12:53 ET Detox Gallery Presents "I Grieve Different" -- A Month-Long Art Exhibition Exploring Grief, Healing, and Collective Humanity
THC/CBD-infused beverages provided by Ayrloom & TBD.Community & Wellness Programming: The month includes soundbath meditation sessions with MG Jarrett, a yoga and end-of-year journaling workshop, and a vision-boarding session for 2026 led by Artgurl, a women-powered creative organization specializing
More news about: DETOX GALLERY
Dec 10, 2025, 10:11 ET Menarini Group、2025年サンアントニオ乳がんシンポジウムにてエラセストラント（ORSERDU®）併用療法の第2相データをER+、HER2-転移性乳がん（mBC）患者を対象に発表
エラセストラント 345mg QD+ エベロリムス 7.5mg QD(n=50)エラセストラント 345mg QD
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 09:30 ET Lawmakers and Advocates Call on Pennsylvania to become the next state to enact water quality management reforms to prevent spread of Legionella and Legionnaires' Disease
include:Public Water System Requirements:Maintain minimum detectable disinfectant levels (0.5 mg/L for chlorine; 1.0 mg/L for chloramine).Develop a distribution system maintenance plan to mitigate the risk of Legionella bacteria.Records
More news about: Prevent Legionnaires'
Dec 10, 2025, 09:00 ET NEW RESEARCH SHOWS RO HELPS PATIENTS ACHIEVE WEIGHT LOSS AND SAFETY OUTCOMES CONSISTENT WITH CLINICAL TRIALS
median baseline body mass index (BMI) of 32.3 kg/m² (IQR 30.2-35.5) and baseline median weight of 94.3 kg. At 68 weeks, 52.1% of patients were on a 2.4 mg dose of semaglutide.ResultsAmong 655 participants (445 women and 210 men), the average body weight reduction was 16.6% (SD 7.5;
More news about: Ro
Dec 10, 2025, 07:00 ET Consumers report feeling lighter, more motivated, mindful, and happier with Montoloeder's Metabolaid® weight-control formulation
The US-based consumer study drew the opinions of 112 adult participants who took a 500mg daily dose of the botanical supplement for a period of eight weeks. They also completed a self-assessment questionnaire at the end of each week to document
More news about: Monteloeder, S.L.
Dec 10, 2025, 00:47 ET Kapture CX Reports Sustained Profitability, 80% YoY Growth; Eyes 2.5× Expansion Over Next 12 Months
profitable foundation, robust growth trajectory, and differentiated vertical-first full-stack AI strategy backed by marquee clients like BigBasket, Tata 1mg, Aditya Birla Capital, Coca-Cola, Reliance, and many more. Kapture CX is set to redefine enterprise employee-experience automation for both India and
More news about: Kapture CX
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
Elacestrant 345 mg una volta al giorno+ everolimus 7,5 mg una volta al giorno(n=50)
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 16:00 ET Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT) Forum 2025
InflammationReduced high-sensitivity C-reactive protein (hsCRP) in participants with hsCRP above 3 mg/L at baseline by approximately 40%; person with hsCRP >3 mg/L are at high risk for future cardiovascular events. Lipid Profile and other
More news about: Cirius Therapeutics
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
345 mg 每日一次+ Everolimus 7.5mg 每日一次(n = 50)Elacestrant 345 mg 每日一次
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
Elacestrant 345 mg QD + Everolimus 7,5 mg QD (n=50) Elacestrant 345 mg QD
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
엘라세스트란트 345mg 1일 1회+ 에버로리무스 7.5mg 1일 1회(n=50)엘라세스트란트 345mg 1일 1회
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:00 ET Clinical Trial Shows Pycnogenol® Significantly Relieves Lipedema Symptoms and Improves Quality of Life in Women
Pycnogenol® in managing the condition. Participants were monitored over a 60-day period, with half receiving Pycnogenol® (50 mg, three times daily) and half receiving a placebo.Researchers evaluated quality of life, body composition and symptom severity at the start,
More news about: Horphag Research (USA) Inc.
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia
weeks. In addition, patients were randomly assigned to receive four once-monthly infusions of a lower dose of ianalumab (3 mg per kilogram of body weight), a higher dose ianalumab (9 mg per kilogram), or a placebo. The study's primary endpoint was time to treatment failure, defined as elapsed time
More news about: American Society of Hematology
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.About Chronic Lymphocytic Leukemia/Small
More news about: Eli Lilly and Company
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
Golidocitinib 75mg daily with CHOP, followed by 150mg maintenance after CHOP, showed an ORR of 94.1% and a CR rate of 64.7%. By the data cutoff date, 85% of patients remained on treatment.Golidocitinib 150mg daily with CHOP, followed by 150mg maintenance after CHOP, showed an
More news about: Dizal Pharmaceutical
Dec 08, 2025, 19:00 ET Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
maintained in both 100 mg and 200 mg maintenance groups, whereas the corresponding withdrawal groups exhibited median efficacy durability of 20.4 weeks and 24.6 weeks (32.4 weeks and 36.6 weeks post-last dose of picankibart), respectively. Maintenance treatment with picankibart 100 mg and 200 mg significantly
More news about: Innovent Biologics
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
Elacestrant 345 mg QD+ Everolimus 7,5 mg QD(n=50)Elacestrant 345 mg QD
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
Elacestrant 345 mg QD+ Everolimus 7,5mg QD(n=50)Elacestrant 345 mg QD
More news about: Menarini Industrie Farmaceutiche Riunite